- POSITIVE
Annual Revenue Remus Pharma Mar-2026 Annual Revenue is Rs 101 Cr which is growth of 22.9% YoY.
- POSITIVE
Annual Net Profit Remus Pharma Mar-2026 Annual Net Profit is Rs 25 Cr which is growth of 24.2% YoY.
aboutRemus Pharmaceuticals Ltd. operates as a pharmaceutical company primarily engaged in the marketing and distribution of finished dosage formulations. The company serves various therapeutic segments, focusing on export markets to enhance its global foo... Read More
831.00-12.35(-1.46%)
8,100
NSE Volume
NSE 02 Nov, 2026 3:31 PM (IST)
Please subscribe to view forecaster data
Remus Pharma Stock Price Analysis
Day Price Range-1.5% 1 Day return | 831 (LTP) 821873 LowHigh |
|---|---|
Week Price Range-5.6% 1 Week return | 831 (LTP) 821905 LowHigh |
Month Price Range-3.6% 1 Month return | 831 (LTP) 8211,039 LowHigh |
52 Week Price Range15.4% 1 Year return | 831 (LTP) 5801,039 LowHigh |
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Remus Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 |
|---|---|---|---|---|---|---|---|---|---|---|
29.3% | 39.3% | 100.8 | 82.1 | 67.2 | 46.6 | 25.4 | 19.2 | 12.8 | ||
Operating Exp. Ann. | 23.1% | 29.4% | 64.3 | 53.2 | 43.5 | 34.5 | 20.7 | 17.7 | 11.5 | |
Operating Profit Ann. | 41% | 106% | 29.7 | 26 | 20 | 10.6 | 4.1 | 0.8 | 0.4 | |
OPM Ann. % | 9.2% | 49.4% | 29.48% | 31.66% | 29.83% | 22.63% | 16.00% | 3.96% | 3.07% | |
24.3% | 30.4% | 67.6 | 55.4 | 44.7 | 35.2 | 20.9 | 17.9 | 11.7 | ||
EBITDA Ann. | 44.6% | 87% | 36.6 | 28.9 | 23.7 | 12.1 | 4.8 | 1.6 | 1.2 | |
EBITDA Ann. margin % | 11.7% | 34.8% | 36.26% | 35.20% | 35.33% | 26.01% | 18.83% | 8.16% | 9.73% | |
Interest Ann. | 44.2% | - | 0.6 | 0.4 | 0.3 | 0.2 | 0.1 | 0 | 0 | |
Depr. | 77.6% | 69.5% | 2.8 | 1.9 | 0.9 | 0.5 | 0.2 | 0.2 | 0.1 | |
PBT Ann. | 42.8% | 88.4% | 33.2 | 26.6 | 22.5 | 11.4 | 4.6 | 1.4 | 1.1 | |
Tax Ann. | 43.1% | 95.2% | 8.5 | 6.7 | 5.7 | 2.9 | 1.2 | 0.3 | 0.3 | |
42.7% | 89.9% | 24.7 | 19.9 | 16.8 | 8.5 | 3.4 | 1 | 0.8 | ||
Net Profit Ann. | 42.7% | 89.9% | 24.7 | 19.9 | 16.8 | 8.5 | 3.4 | 1 | 0.8 | |
NPM Ann. % | 11.7% | 36.4% | 26.29% | 25.13% | 26.48% | 18.88% | 13.69% | 5.56% | 6.80% | |
EPS Adj. latest Ann. | 42.9% | 87.8% | 21 | 16.9 | 14.3 | 7.2 | 2.9 | 0.9 | 0.7 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
22.8%
2Y CAGR
22.5%
3Y CAGR
29.3%
5Y CAGR
39.3%
Net Profit Ann.
1Y CHG
24.1%
2Y CAGR
21.3%
3Y CAGR
42.7%
5Y CAGR
89.9%
Operating Exp. Ann.
1Y CHG
20.9%
2Y CAGR
21.6%
3Y CAGR
23.1%
5Y CAGR
29.4%
Remus Pharma Technical Analysis
Remus Pharma EMA & SMA
Bearish-6
1 bullish, 7 bearish
Bullish1
Bearish7
| 5 Day | 858.2 |
|---|---|
| 10 Day | 881.6 |
| 12 Day | 887.7 |
| 20 Day | 901.2 |
| 26 Day | 904.5 |
|---|---|
| 50 Day | 895.1 |
| 100 Day | 856.1 |
| 200 Day | 820.8 |
Remus Pharma Delivery And Volume
Daily Avg. Delivery Volume %
02 Nov, 202693.8%
Week81.2%
Month75.0%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Remus Pharma Resistance and Support
841.65
Pivot
| First Resistance | 862.3 |
|---|---|
| Second Resistance | 893.6 |
| Third Resistance | 914.3 |
| First Support | 810.4 |
|---|---|
| Second Support | 789.7 |
| Third Support | 758.4 |
| Day RSI | 37.7 |
|---|---|
| Day MACD | -16.8 |
| Day MFI | 54.5 |
| Day MACD Signal Line | -3 |
Remus Pharma Beta
| 1 Month | -1.6 |
|---|---|
| 1 Year | 0.3 |
| 3 Month | 0.1 |
|---|---|
| 3 Year | 0.2 |
Remus Pharma Price Change Analysis
↓-3.6%
Over 1 Month
LowHigh
8211039
↑15.4%
Over 3 Months
LowHigh
7251039
↑21.3%
Over 6 Months
LowHigh
6791039
↑15.4%
Over 1 Year
LowHigh
5801039
Remus Pharma Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| BLUE LOTUS CAPITAL MULTI BAGGER FUND II | Bulk | Sell | 07 Aug 2026 | 830.19 | 63,900 | NSE |
| CHHATTISGARH INVESTMENTS LIMITED | Bulk | Sell | 26 Jul 2023 | 3599.03 | 8,000 | NSE |
| JINENDRA G | Bulk | Purchase | 15 Jun 2023 | 2387.92 | 7,500 | NSE |
| YUGA STOCKS AND COMMODITIES PRIVATE LIMITED . | Bulk | Sell | 01 Jun 2023 | 2079.90 | 10,600 | NSE |
| INDIA EMERGING GIANTS FUND LIMITED | Bulk | Purchase | 01 Jun 2023 | 2079.23 | 15,700 | NSE |
| MONEYWISE FINANCIAL SERVICES PRIVATE LTD | Bulk | Sell | 29 May 2023 | 1712.85 | 10,700 | NSE |
| JAIN SANJAY POPATLAL | Bulk | Purchase | 29 May 2023 | 1711.25 | 10,000 | NSE |
| NEGEN CAPITAL SERVICES PRIVATE LIMITED | Bulk | Purchase | 29 May 2023 | 1793.90 | 34,000 | NSE |
| GPRAKASHCHAND BAID HUF | Bulk | Purchase | 29 May 2023 | 1711.25 | 8,000 | NSE |
Remus Pharma Corporate Actions
Remus Pharma Dividend history and yield
Remus Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Remus Pharma dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
122 Sep 2026 | 0.5 | FINAL | 22 Sep 2026 | Equity Share |
214 Nov 2025 | 0.5 | INTERIM | 14 Nov 2025 | Equity Share |
318 Sep 2025 | 0.5 | FINAL | 18 Sep 2025 | Equity Share |
419 Nov 2024 | 1 | INTERIM | 20 Nov 2024 | Equity Share |
502 May 2024 | 4 | INTERIM | 02 May 2024 | Equity Share |
Remus Pharma Bonus shares
Remus Pharma bonus history along with announcement, record, ex-bonus dates, and bonus ratios.
#Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
104 Jul 2025 | 1:1 | 04 Jul 2025 |
206 Jun 2024 | 3:1 | 06 Jun 2024 |
Remus Pharma Board Meetings
Remus Pharma past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
120 May 2026 | Audited Results, Dividend & Others | To consider other business matters. |
210 Nov 2025 | Quarterly Results & Interim Dividend | - |
317 May 2025 | Audited Results, Dividend & Others | To consider 1. Bonus 2. Other business matters. |
409 Nov 2024 | Quarterly Results & Interim Dividend | To consider other business matters. |
516 May 2024 | Audited Results | - |
Remus Pharma - Company Profile
Remus Pharma Management Structure
Remus Pharma management structure with salaries, total experience, and qualifications.
Remus Pharma Board of Directors
Remus Pharma Board of directors with salaries, total experience, and qualifications.
Website: www.remuspharma.com
About the company - Business Profile
Remus Pharmaceuticals Ltd. operates as a pharmaceutical company primarily engaged in the marketing and distribution of finished dosage formulations. The company serves various therapeutic segments, focusing on export markets to enhance its global footprint. It leverages a decentralized manufacturing model, often collaborating with third-party manufacturers to produce a wide range of pharmaceutical products.
Key Points
- Key Facts: Remus Pharmaceuticals Ltd. was incorporated in 2015 and is headquartered in Ahmedabad, Gujarat. The company is listed on the NSE SME platform. Its core business involves the distribution of a diverse portfolio of pharmaceutical products including tablets, capsules, and injectables.
- Operations and Resources: The company operates through a network of contract manufacturers, which allows for a flexible and scalable production process. Notable assets include its marketing and distribution infrastructure tailored for emerging and semi-regulated markets.
- Privatization and Ownership: As of the latest filings, the company remains promoter-driven with Swapnil Jatinbhai Shah as a key figure in management. There is no significant government stake reported.
- Market and Significance: Remus serves a broad spectrum of industries within healthcare, specifically targeting therapeutic areas like anti-diabetics, cardiovascular, and antibiotics. Its strategic importance lies in providing cost-effective generic alternatives in international markets.
- Business Model: The company's business model is centered on asset-light operations. It excels in managing global supply chains and regulatory filings (dossiers) for various geographies, enabling rapid market entry for its products.
- Revenue Breakdown:
- By Geography: A significant portion of revenue is derived from exports, particularly to regions like the Middle East, Africa, and Southeast Asia.
- By Segment: The company operates under a single primary segment: Pharmaceutical Products.
- Key Products and Services:
- Finished formulations across various dosage forms: Tablets, Capsules, Liquid Orals, and Ointments.
- Therapeutic Focus: High preference is given to cardiovascular, anti-bacterial, and gastrointestinal products.
- Employees: The company maintains a lean workforce, focusing on regulatory affairs, quality control, and international marketing.
Strategic Initiatives and Future Outlook Current initiatives focus on expanding the product portfolio into more complex generics and increasing presence in regulated markets. The company is actively pursuing new marketing authorizations to diversify its geographical reach and mitigate regional risks.
References